<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027556</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2019-0344</org_study_id>
    <nct_id>NCT04027556</nct_id>
  </id_info>
  <brief_title>Reducing Iodine Dose Based on Lean Body Weight</brief_title>
  <official_title>Detection of Hepatocellular Carcinomas Using Virtual Monoenergetic Imaging With Reduced Iodine Dose Based on Lean Body Weight</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Corporation, Corporate Technology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess whether the acceptable image quality is achievable using low&#xD;
      contrast media dose calculated based on lean body weight and low keV imaging for the&#xD;
      detection of hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, the contrast media dose is calculated based on total body weight. However, the&#xD;
      human body is composed of adipose tissue and non-adipose tissue, and adipose tissue&#xD;
      contributes little to the volume of distribution for contrast media. Therefore, iodine dose&#xD;
      calculated based on lean body weight would be more personalized than merely considering total&#xD;
      body weight. In addition, lowering the contrast media dose would be achievable by using&#xD;
      virtual monoenergetic imaging at low keV. Therefore, we aimed to assess whether the&#xD;
      acceptable image quality is achievable using low contrast media dose calculated based on lean&#xD;
      body weight and low keV imaging for the detection of hepatocellular carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lesion conspicuity</measure>
    <time_frame>6 months after complete enrollment</time_frame>
    <description>qualitative scoring for focal lesion depiction on four-point scale (1: worst, 4: excellent, representative value is average score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image noise</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>qualitative scoring for image noise on four-point scale (1: worst, 4: excellent, representative value is average score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image contrast</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>qualitative scoring for image contrast on four-point scale (1: worst, 4: excellent, representative value is average score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall image quality</measure>
    <time_frame>6 months after complete enrollment</time_frame>
    <description>qualitative scoring for image quality on four-point scale (1: worst, 4: excellent, representative value is average score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion detection</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>assessment of focal liver lesion (HCC) on CT according to Liver Imaging Reporting and Data System (LI-RADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hounsfield unit</measure>
    <time_frame>3 months after complete enrollment</time_frame>
    <description>measurement of hounsfield unit in aorta, portal vein, liver parenchyma, and paraspinal muscles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast media dose</measure>
    <time_frame>3 months after complete enrollment</time_frame>
    <description>administered contrast media dose in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation dose</measure>
    <time_frame>3 months after complete enrollment</time_frame>
    <description>measured radiation dose in each group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Body Weight</condition>
  <arm_group>
    <arm_group_label>Low dose - lean body weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low CT contrast media dose calculated based on lean body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard CT contrast media dose calculated based on total body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low dose CT contrast media - lean body weight</intervention_name>
    <description>CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.</description>
    <arm_group_label>Low dose - lean body weight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard dose CT contrast media</intervention_name>
    <description>CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.</description>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High risk group for developing HCC&#xD;
&#xD;
          -  Scheduled contrast-enhanced CT for HCC diagnosis or surveillance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not a high risk group for developing HCC&#xD;
&#xD;
          -  body mass index is equal to or larger than 30 kg/m^2&#xD;
&#xD;
          -  suspected HCC &gt; 5cm in diameter&#xD;
&#xD;
          -  received locoregional treatment or surgery for HCC within 3 months&#xD;
&#xD;
          -  congestive hepatopathy&#xD;
&#xD;
          -  no venous access on forearm&#xD;
&#xD;
          -  anticipated beam hardening artifact due to prosthesis&#xD;
&#xD;
          -  relative/absolute contraindication of contrast-enhanced CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

